Ionis pharmaceuticals, inc. (IONS)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08
Revenue:
Revenue

1,122,599

599,674

514,179

372,776

283,703

214,161

147,285

102,049

99,086

108,473

121,600

107,190

Expenses:
Cost of products sold

4,384

1,820

0

0

-

-

-

-

-

-

-

-

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sa

465,688

414,604

374,644

344,320

322,292

241,751

184,033

158,458

157,397

145,160

134,623

106,439

Selling, general and administrative

286,644

244,622

108,488

48,616

37,173

20,140

14,918

12,515

12,789

11,669

14,515

13,811

Total operating expenses

756,716

661,046

483,132

392,936

359,465

261,891

198,951

170,973

170,186

156,829

149,138

120,250

Income (loss) from operations

365,883

-61,372

31,047

-20,160

-75,762

-47,730

-51,666

-68,924

-71,100

-48,356

-27,538

-13,060

Other income (expense):
Equity in net loss of Regulus Therapeutics Inc.

-

-

-

-

-

-

-

-1,406

-3,554

-6,879

-

-

Investment income

52,205

30,187

8,179

5,472

4,377

2,682

2,085

1,844

2,414

3,370

6,361

11,318

Interest expense

48,768

44,789

44,752

38,795

36,732

22,209

19,355

21,152

16,732

13,232

12,672

11,812

Gain on investments, net

-

-

-

-

-

1,256

2,378

1,465

4,182

-713

2,084

-965

Gain on investment in Regulus Therapeutics Inc.

-

-

-

-

20,211

19,902

0

18,356

-

4,651

-

-

Difference between the purchase price of the facility and the carrying value of our financing liability at the time of the purchase.

0

0

-7,689

0

0

-

-

-

-

-

-

-

Loss on early retirement of debt

-21,865

0

0

-3,983

0

-8,292

0

-4,770

-

-

-

-

Other expenses

-686

-182

-3,548

0

0

-

-

-

-

-

-

-

Income (loss) before income tax benefit (expense)

346,769

-76,156

-16,763

-57,466

-87,906

-54,391

-66,558

-74,587

-84,790

-61,159

-31,765

-14,519

Income tax benefit (expense)

43,507

-291,141

-5,980

2,934

372

-15,407

-5,914

-9,109

11

92

3,191

-

Net loss from continuing operations

-

-

-

-

-

-

-

-

-

-

-34,956

-14,519

Loss from discontinued operations

-

-

-

-

-

-

-

-

-

-

-29

-8,387

Gain on sale of Ibis Biosciences, Inc., net of tax

-

-

-

-

-

-

-

-

-

-

185,657

-

Net income from discontinued operations, net of tax

-

-

-

-

-

-

-

-

-

-

185,628

-8,387

Net income (loss)

303,262

214,985

-10,783

-60,400

-88,278

-

-

-

-

-

150,672

-22,906

Net (income) loss attributable to noncontrolling interest in Akcea Therapeutics, Inc.

9,116

-58,756

-11,129

0

0

-

-

-

-

-

-4,394

-4,734

Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders

294,146

273,741

346

-60,400

-88,278

-38,984

-60,644

-65,478

-84,801

-61,251

155,066

-18,172

Basic and diluted net loss per share (in dollars per share)

-

-

-

-

-

-0.33

-0.55

-0.65

-0.85

-0.62

-

-

Shares used in computing basic and diluted net loss per share (in shares)

-

-

-

-

-

117,691

110,502

100,576

-

-

-

-

Net loss from continuing operations attributable to Isis Pharmaceuticals, Inc. common stockholders, Basic (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-0.31

-0.10

Net income from discontinued operations, Basic (in dollars per share)

-

-

-

-

-

-

-

-

-

-

1.89

-0.09

Basic net income per share (in dollars per share)

2.12

2.09

0.15

-0.50

-0.74

-

-

-

-

-

1.58

-0.19

Shares used in computing basic net income (loss) per share (in shares)

139,998

132,320

124,016

120,933

119,719

-

-

-

99,656

99,143

98,109

94,566

Net loss from continuing operations attributable to Isis Pharmaceuticals, Inc. common stockholders, Diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-0.31

-0.10

Net income from discontinued operations, Diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

-

1.89

-0.09

Diluted net income per share (in dollars per share)

2.08

2.07

0.15

-0.50

-0.74

-

-

-

-

-

1.58

-0.19

Shares used in computing diluted net income (loss) per share (in shares)

142,872

134,056

126,098

120,933

119,719

-

-

-

99,656

99,143

98,109

94,566

Commercial [Member]
Revenue

352,450

254,922

120,014

22,767

2,343

11,647

3,091

5,634

2,896

5,552

13,469

8,337

Royalty revenues from the sale of SPINRAZA (nusinersen).
Revenue

292,992

237,930

112,540

883

0

-

-

-

-

-

-

-

Revenue from the sale of TEGSEDI (inotersen).
Revenue

42,253

2,237

0

0

-

-

-

-

-

-

-

-

Revenue from license fees and other royalties, excluding royalties from the sale of SPINRAZA.
Revenue

17,205

14,755

7,474

21,884

2,343

-

-

-

-

-

-

-

Revenue from research and development services performed under a collaboration agreement.
Revenue

770,149

344,752

394,165

350,009

281,360

202,514

144,194

96,415

96,190

102,921

108,131

98,853